Discovery of Sirolimus Sensitive Biomarkers in Blood
NCT03304678
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
NIH
Sponsor class
Conditions
Lymphangioleiomyomatosis
Interventions
DRUG:
Sirolimus 2mg
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)